![](/img/cover-not-exists.png)
O0027 Rotigotine transdermal patch provides continuous efficacy in patients with moderate to severe idiopathic restless legs syndrome – 24 month results from a multi-national, multi-centre, open-label, follow-up trial
C. Trenkwalder, K. Stiasny-Kolster, W. Poewe, E. Schollmayer, W.H. OertelVolume:
8
Year:
2007
Language:
english
DOI:
10.1016/s1389-9457(07)70213-7
File:
PDF, 49 KB
english, 2007